Low-dose Naltrexone for Post-COVID Fatigue Syndrome
NCT05430152
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
160
Enrollment
OTHER
Sponsor class
Conditions
Post-Viral Fatigue Syndrome
Interventions
DRUG:
Low-Dose Naltrexone
OTHER:
Placebo
Sponsor
Luis Nacul
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]